Denali Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 445
- Market Cap
- -
- Introduction
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Another ALS Defeat as Denali, Sanofi Disclose Phase II Miss
Denali Therapeutics and Sanofi reported a phase II trial failure for an ALS drug, highlighting the ongoing challenges in developing effective treatments for this neurodegenerative disease.
BofA cuts Denali Therapeutics stock target as ALS trial fails phase 2/3 endpoints
BofA Securities lowered Denali Therapeutics' price target to $30 from $34, maintaining a Buy rating, after DNL343 failed phase 2/3 ALS trial endpoints. Despite this, optimism remains for Denali's brain delivery platform and financial health, with a pivotal 2025 expected for its Hunter syndrome treatment. Denali's stock is seen as undervalued, offering a potential buying opportunity.
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
DNL343, evaluated in the HEALEY ALS Platform Trial, did not meet primary or secondary endpoints at 24 weeks but was safe and well-tolerated. Further analyses, including biomarkers and subgroup data, are expected in 2025. The study underscores the urgent need for effective ALS treatments.
Denali Therapeutics Announces Topline Results for DNL343 in Phase 2/3 HEALEY ALS Platform Trial
Denali Therapeutics announced DNL343 did not meet primary and secondary endpoints in the Phase 2/3 HEALEY ALS Platform Trial for ALS treatment. Despite not showing efficacy in slowing disease progression, DNL343 was safe and well-tolerated. Further analyses, including biomarker studies, are expected in 2025.
Denali reports ALS trial misses primary goals
Denali Therapeutics Inc. announced its Phase 2/3 clinical trial for ALS treatment DNL343 did not meet primary efficacy endpoints. Despite this, DNL343 was safe and well tolerated. The company, financially robust, plans further analyses. ALS affects 30,000 in the U.S. and 500,000 globally. Denali remains committed to ALS treatment research.
Sean M. Healey & AMG Center Announces Topline Results of HEALEY ALS Platform Trial's Regimen G Testing DNL343
The HEALEY ALS Platform Trial's Regimen G, testing DNL343, did not meet primary or key secondary endpoints at 24 weeks but was safe and well-tolerated. Additional analyses, including biomarkers and long-term effects, are expected by 2025. The trial aims to accelerate ALS treatment development, with ongoing commitment to understanding DNL343's effects.
Denali Therapeutics Trial of Potential ALS Treatment Misses Primary Endpoint
Denali Therapeutics Inc. develops therapies crossing the blood-brain barrier for neurodegenerative and lysosomal storage diseases, with seven clinical candidates including DNL310 for MPS II, DNL151 for Parkinson’s, DNL343 for ALS, DNL788 for MS, DNL593 for FTD-GRN, and DNL126 for MPS IIIA.
Denali Therapeutics Announces Topline Results for Regimen G Evaluating DNL343 in the HEALEY ALS Platform Trial
DNL343, evaluated in the Phase 2/3 HEALEY ALS Platform Trial, did not meet primary or key secondary endpoints at 24 weeks but was safe and well-tolerated. Further analyses, including biomarker studies, are expected in 2025. The trial aims to accelerate ALS treatment development.
Denali Therapeutics Announces Topline Results for Regimen in HEALEY ALS Platform Trial
DNL343, evaluated in the Phase 2/3 HEALEY ALS Platform Trial, did not meet primary and key secondary endpoints at 24 weeks but was safe and well-tolerated. Further analyses, including biomarkers and subgroup data, are expected in 2025. ALS, affecting 30,000 in the U.S., urgently needs effective therapies.
© Copyright 2025. All Rights Reserved by MedPath